Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics [Seeking Alpha]
Virios Therapeutics, Inc. (VIRI)
Company Research
Source: Seeking Alpha
Sealbond, an indirect parent of Wex Pharmaceuticals, pursuant to which the companies will combine in an all-stock transaction. The combined company's new name will be Dogwood Therapeutics (DWTX) and it will be focused on the clinical development of three assets: Halneuron, currently in Phase 2b development for chemotherapy-induced neuropathic pain; IMC-1, poised for Phase 3 development as a treatment for fibromyalgia; and IMC-2, currently in Phase 2 development to treat Long-COVID sequelae. In connection with the combination, the company announced that it is raising $19.5 million in a committed debt financing by an affiliate of CKLS in two tranches with $16.5 million funding at closing and an additional $3 million funded in 1Q25, subject to certain customary conditions. This financing is expected to fund research and operations through several key milestones, including the release of results from the Halneuron Phase 2b interim analysis assessment expected in 2H25. Dogwood will
Show less
Read more
Impact Snapshot
Event Time:
VIRI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIRI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIRI alerts
High impacting Virios Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VIRI
News
- Virios Therapeutics, Inc. (NASDAQ: VIRI) had its price target raised by analysts at HC Wainwright from $0.20 to $5.00. They now have a "neutral" rating on the stock.MarketBeat
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, NAPA, VIRI on Behalf of ShareholdersPR Newswire
- VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire
- Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX") [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)GlobeNewswire
VIRI
Earnings
- 8/8/24 - Beat
VIRI
Sec Filings
- 10/7/24 - Form DEFA14A
- 10/7/24 - Form 8-K
- VIRI's page on the SEC website